Search research articles
Contact Us
Filters
Showing results (41-50 of 82) with videos related to
Page
of 9
Sort By:
Heliyon
|
September 18, 2024
Neuron-derived Netrin-1 deficiency aggravates spinal cord injury through activating the NF-κB signaling pathway
Xiaojian Qin, Xiaolan Zhang, Xiaodong He, et al.
Dermatology and Therapy
|
May 11, 2024
Unmet Needs and Treatment Preference of Systemic Treatments for Moderate-to-Severe Psoriasis from the Perspectives of Patients and Dermatologists in China
Yehong Kuang, Yuzhen Li, Chengzhi Lv, et al.
Chemical Science
|
November 11, 2021
Late-stage modification of peptides and proteins at cysteine with diaryliodonium salts
Stephen A Byrne, Max J Bedding, Leo Corcilius, et al.
The Journal of Dermatology
|
December 6, 2024
Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient-reported outcomes in the POETYK PSO-4 study
Yayoi Tada, April W Armstrong, Shinichi Imafuku, et al.
Dermatology and Therapy
|
October 6, 2023
Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis
April W Armstrong, Richard B Warren, Yichen Zhong, et al.
Journal of Medical Economics
|
May 16, 2020
The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States
Rachael Louise Slater, Yizhen Lai, Yichen Zhong, et al.
Plos One
|
December 11, 2014
Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies
Daniel Y Heng, James Signorovitch, Elyse Swallow, et al.
Nature Nanotechnology
|
July 27, 2023
Close the cancer-immunity cycle by integrating lipid nanoparticle-mRNA formulations and dendritic cell therapy
Yuebao Zhang, Xucheng Hou, Shi Du, et al.
European Urology Oncology
|
August 15, 2019
Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden
Tushar Srivastava, Vimalanand S Prabhu, Haojie Li, et al.
Microbiological Research
|
December 20, 2024
Development of Etf-3-specific nanobodies to prevent Ehrlichia infection and LNP-mRNA delivery in cellular and murine models
Nan Duan, Mingqun Lin, Wenqing Zhang, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 82) with videos related to
Sort By:
Page
of 9
Heliyon
|
September 18, 2024
Neuron-derived Netrin-1 deficiency aggravates spinal cord injury through activating the NF-κB signaling pathway
Xiaojian Qin, Xiaolan Zhang, Xiaodong He, et al.
Dermatology and Therapy
|
May 11, 2024
Unmet Needs and Treatment Preference of Systemic Treatments for Moderate-to-Severe Psoriasis from the Perspectives of Patients and Dermatologists in China
Yehong Kuang, Yuzhen Li, Chengzhi Lv, et al.
Chemical Science
|
November 11, 2021
Late-stage modification of peptides and proteins at cysteine with diaryliodonium salts
Stephen A Byrne, Max J Bedding, Leo Corcilius, et al.
The Journal of Dermatology
|
December 6, 2024
Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient-reported outcomes in the POETYK PSO-4 study
Yayoi Tada, April W Armstrong, Shinichi Imafuku, et al.
Dermatology and Therapy
|
October 6, 2023
Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis
April W Armstrong, Richard B Warren, Yichen Zhong, et al.
Journal of Medical Economics
|
May 16, 2020
The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States
Rachael Louise Slater, Yizhen Lai, Yichen Zhong, et al.
Plos One
|
December 11, 2014
Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies
Daniel Y Heng, James Signorovitch, Elyse Swallow, et al.
Nature Nanotechnology
|
July 27, 2023
Close the cancer-immunity cycle by integrating lipid nanoparticle-mRNA formulations and dendritic cell therapy
Yuebao Zhang, Xucheng Hou, Shi Du, et al.
European Urology Oncology
|
August 15, 2019
Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden
Tushar Srivastava, Vimalanand S Prabhu, Haojie Li, et al.
Microbiological Research
|
December 20, 2024
Development of Etf-3-specific nanobodies to prevent Ehrlichia infection and LNP-mRNA delivery in cellular and murine models
Nan Duan, Mingqun Lin, Wenqing Zhang, et al.
Page
of 9